Therapeutic Classification: antiasthmatics, bronchodilators, vasopressors
Pharmacologic Classification: adrenergics
High Alert
Absorption: IV administration results in complete bioavailability; well absorbed following SUBQ and intranasal administration; some absorption may occur following repeated inhalation of large doses.
Distribution: Does not cross the blood-brain barrier.
Half-Life: Unknown.
(bronchodilation)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
Inhaln | 1 min | unknown | 13 hr |
SUBQ | 510 min | 20 min | <14 hr |
IM | 612 min | unknown | <14 hr |
IV | rapid | 20 min | 2030 min |
Intranasal | 510 min | 2030 min | 1 hr |
Contraindicated in:
Use Cautiously in:
CV: angina, arrhythmias, hypertension, tachycardia
Derm: skin and soft tissue infections (including necrotizing fasciitis and myonecrosis)
EENT: intranasal paresthesia (intranasal), nasal discomfort (intranasal), throat irritation (intranasal), nasal congestion (intranasal), nasal pruritus (intranasal), rhinorrhea (intranasal), sneezing (intranasal)
Endo: hyperglycemia
GI: abdominal pain (intranasal), nausea, vomiting
GU: renal impairment
Neuro: dizziness (intranasal), headache, nervousness, restlessness, tremor, insomnia
Resp: PARADOXICAL BRONCHOSPASM (WITH EXCESSIVE USE OF INHALERS), pulmonary edema
Drug-drug:
Drug-Natural Products:
Lab Test Considerations:
Toxicity and Overdose:
IV Administration:
NDC Code